Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.43 |
| ▸ | NPY1R | P25929 | 7/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
| ▸ | SCTR | P47872 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31453827 | 0.94 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL38660264 | 0.94 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL31399748 | 0.94 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL31453796 | 0.93 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30291866 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RKLK7 | |
| SCHEMBL30866245 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30905088 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RKLK7 | |
| SCHEMBL31088231 | 0.93 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29736425 | 0.93 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL4957131 | 0.92 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471490-B2 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | TORQUE THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11471490-B2 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | CD4, ICOS, IL2 | NPY4R 2533/4885NPY1R 2316/4885NPY2R 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.